The Role of Cytoreductive Nephrectomy: European Association of Urology Recommendations in 2016

详细信息    查看全文

• 作者：Axel Bex^a ; ^&dagger ; ; ^{a.bex@nki.nl" class="auth_mail" title="E-mail the corresponding author} ; Bö ; rje Ljungberg^b ; ^&dagger ; ; Hein van Poppel^c ; ^&Dagger ; ; Thomas Powles^d ; ^&dagger ; ; on behalf of the European Association of Urology
• 关键词：Renal cell cancer ; Management ; Metastatic ; Nephrectomy ; Cytoreductive ; Performance score ; EAU ; Guidelines
• 刊名：European Urology
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：70
• 期：6
• 页码：901-905
• 全文大小：227 K

文摘

After the introduction of systemic targeted therapies, the use of nephrectomy in patients with metastatic renal cell carcinoma has declined. Currently, systemic therapy is offered to more patients first as a means to select those candidates that will likely benefit from removal of their primary tumour. Although studies consistently demonstrate a survival benefit after nephrectomy, most patients with poor risk metastatic disease are unlikely to benefit from surgery. Soon studies will report on the effect of nephrectomy in patients with metastatic disease at diagnosis.